Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH; Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer. Van Kesteren Ch, et al. Among authors: droz jp. J Clin Oncol. 2002 Oct 1;20(19):4065-73. doi: 10.1200/JCO.2002.01.005. J Clin Oncol. 2002. PMID: 12351604
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
Terret C, Zanetta S, Roché H, Schellens JH, Faber MN, Wanders J, Ravic M, Droz JP; EORTC Early Clinical Study Group. Terret C, et al. Among authors: droz jp. Eur J Cancer. 2003 May;39(8):1097-104. doi: 10.1016/s0959-8049(03)00128-x. Eur J Cancer. 2003. PMID: 12736109 Clinical Trial.
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
de Jonge MJ, Droz JP, Paz-Ares L, van Oosterom AT, de Wit R, Chollet P, Baron B, Lacombe D, Mettinger K, Fumoleau P; EORTC-New Drug Development Group/New Drug Development Program. de Jonge MJ, et al. Among authors: droz jp. Invest New Drugs. 2004 Aug;22(3):329-33. doi: 10.1023/B:DRUG.0000026260.24275.02. Invest New Drugs. 2004. PMID: 15122081 Clinical Trial.
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR. Schöffski P, et al. Among authors: droz jp. Ann Oncol. 1999 Jan;10(1):119-22. doi: 10.1023/a:1008360323986. Ann Oncol. 1999. PMID: 10076732 Free article. Clinical Trial.
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, Fumoleau P; European Organization for Research and Treatment of Cancer (EORTC). Coudert B, et al. Among authors: droz jp. Eur J Cancer. 2001 Nov;37(17):2194-8. doi: 10.1016/s0959-8049(01)00286-6. Eur J Cancer. 2001. PMID: 11677106 Clinical Trial.
471 results